1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Evento
Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/46519
Registro completo de metadatos
Campo DCValorIdioma
dc.creatorCristiane Aparecida Menezes de Páduapt_BR
dc.creatorPaula Lana de Miranda Drummondpt_BR
dc.creatorRoberta Márcia Marques dos Santospt_BR
dc.date.accessioned2022-10-24T13:18:56Z-
dc.date.available2022-10-24T13:18:56Z-
dc.date.issued2017-08-22-
dc.citation.issue33pt_BR
dc.citation.spage388pt_BR
dc.citation.epage388pt_BR
dc.identifier.doihttps://doi.org/10.1002/pds.4275pt_BR
dc.identifier.issn1099-1557pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/46519-
dc.description.resumoBackground: In Brazil, thalidomide (TLD) is the firstline treatment for Erythema Nodosum Leprosum (ENL) in patients with Hansen’s disease. The lack of information concerning adverse drug reactions (ADR) related to TLD and the incipient surveillance has motivated this study. Objectives: To estimate the frequency of ADR associated with TLD use in patients with ENL. In addition, issues related to prescription, dispensing and pharmacovigilance activities of TLD were evaluated. Methods: Cross-sectional study involving patients attending dermatologic clinics of a public referral hospital for infectious diseases in Minas Gerais State, Brazil. All patients (≥18 years) using TLD for ENL between July and October 2016 were invited to participate in the study. Patients were interviewed and asked to respond to questions about sociodemographic variables, variables related to their health state, understanding of TLD treatment, accordance with national regulatory law, and ADR experienced during the treatment. Results: A total of 110 patients were interviewed. Most were men (65.5%) aged on average 47.8 years old. The mean length of TLD use was 37.3 months. Twenty-three out of 38 women reported the use of injectable medroxyprogesterone, 16.7% had been submitted to a previous sterilization procedure, 19.4% were not in fertile age, and 33.7% of patients referred condom use. Approximately 80.0% of the patients knew they used TLD for ENL or Hansen’s disease whereas 19.3% were not aware about the reason of TLD’s use. Most ADR comprised dry skin (94.6%), paresthesia (82.7%), somnolence (77.3%), weight gain (66.4%), tremor (60.9%), adynamia (60.0%), pain (52.7%), dry mouth (52.7%), anxiety (52.7%), impotence (25.5%), lower limb edema (20.9%) and thrombosis (6.4%). Conclusions: ADR were very common among TLD patients. Women in fertile age are under contraceptive use to ensure birth control, but not all patients reported the use of condom. Apparently, most patients understand the need of TLD and perceive the main adverse effects.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIALpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofInternational Conference on Pharmacoepidemiology & Therapeutic Risk Managementpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectReações adversas a medicamentospt_BR
dc.subjectTalidomidapt_BR
dc.subjectHanseníasept_BR
dc.subject.otherReações adversas a medicamentospt_BR
dc.subject.otherHanseníasept_BR
dc.titleAdverse drug reactions to thalidomide in hansen’s disease patientspt_BR
dc.typeArtigo de Eventopt_BR
dc.url.externahttps://onlinelibrary.wiley.com/doi/full/10.1002/pds.4275pt_BR
Aparece en las colecciones:Artigo de Evento

archivos asociados a este elemento:
archivo Descripción TamañoFormato 
Adverse Drug Reactions to Thalidomide in Hansen’s Disease Patients.pdf61.32 kBAdobe PDFVisualizar/Abrir
Mostrar registro simple del elemento Visualizar estadísticas


Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.